Recent advances in immunotherapy and combination therapies are revolutionizing the treatment landscape for both metastatic ...

Distant metastasis-free survival: the time which cancer does not spread to distant organs ... provide additional support for ...

Therefore future research should also try to assess whether class I HDACs have a prognostic value in locally advanced invasive or metastatic urothelial cancer.

November 4, 2024 Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad® (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, ...

Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the ...

For our methodology, we used a stock screener and selected healthcare stocks that had an RSI below 30, mid-market cap, and ...

SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] The Subject Expert Commit ...

Activating FGFR alterations are present in about 50% to 80% of patients with advanced bladder cancer, and these are known to ...

Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates.

KEYTRUDA, in combination with enfortumab vedotin, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. KEYTRUDA, as a single agent, is indicated for ...